Cargando…

Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection

We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and n...

Descripción completa

Detalles Bibliográficos
Autores principales: Inada, Makoto, Ishikane, Masahiro, Terada, Mari, Matsunaga, Akihiro, Maeda, Kenji, Iwamoto, Noriko, Ujiie, Mugen, Kutsuna, Satoshi, Morioka, Shinichiro, Ishizaka, Yukihito, Mitsuya, Hiroaki, Ohmagari, Norio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925083/
https://www.ncbi.nlm.nih.gov/pubmed/35306204
http://dx.doi.org/10.1016/j.ijid.2022.03.017
_version_ 1784669993096445952
author Inada, Makoto
Ishikane, Masahiro
Terada, Mari
Matsunaga, Akihiro
Maeda, Kenji
Iwamoto, Noriko
Ujiie, Mugen
Kutsuna, Satoshi
Morioka, Shinichiro
Ishizaka, Yukihito
Mitsuya, Hiroaki
Ohmagari, Norio
author_facet Inada, Makoto
Ishikane, Masahiro
Terada, Mari
Matsunaga, Akihiro
Maeda, Kenji
Iwamoto, Noriko
Ujiie, Mugen
Kutsuna, Satoshi
Morioka, Shinichiro
Ishizaka, Yukihito
Mitsuya, Hiroaki
Ohmagari, Norio
author_sort Inada, Makoto
collection PubMed
description We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection.
format Online
Article
Text
id pubmed-8925083
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-89250832022-03-17 Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection Inada, Makoto Ishikane, Masahiro Terada, Mari Matsunaga, Akihiro Maeda, Kenji Iwamoto, Noriko Ujiie, Mugen Kutsuna, Satoshi Morioka, Shinichiro Ishizaka, Yukihito Mitsuya, Hiroaki Ohmagari, Norio Int J Infect Dis Case Report We present a case of a 58-year-old Japanese man with a history of 2 previous COVID-19 infections, who received 2 doses of mRNA-1273 vaccine. We are not aware of any previous study regarding antibody tendency after 2 infections and 2 vaccinations. We evaluated his IgG titer of antispike protein and neutralizing activity from the first infection before and after 2 doses of vaccine. Both antispike IgG titer and neutralizing activity showed a tendency to decline almost 1 year after initial infection; they rapidly increased after the first vaccination, and they remained high after the second vaccination. Although this is a single case report, it seems to have generalizability because the findings are consistent with previous reports regarding single infections or 3 doses of vaccination. Our findings suggest that a single booster shot may provide sufficient protection and aid the understanding of immunologic responses of vaccination in patients with COVID-19 with history of re-infection. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-06 2022-03-16 /pmc/articles/PMC8925083/ /pubmed/35306204 http://dx.doi.org/10.1016/j.ijid.2022.03.017 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Case Report
Inada, Makoto
Ishikane, Masahiro
Terada, Mari
Matsunaga, Akihiro
Maeda, Kenji
Iwamoto, Noriko
Ujiie, Mugen
Kutsuna, Satoshi
Morioka, Shinichiro
Ishizaka, Yukihito
Mitsuya, Hiroaki
Ohmagari, Norio
Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
title Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
title_full Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
title_fullStr Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
title_full_unstemmed Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
title_short Antibody responses after two doses of SARS-CoV-2 mRNA-1273 vaccine in an individual with history of COVID-19 re-infection
title_sort antibody responses after two doses of sars-cov-2 mrna-1273 vaccine in an individual with history of covid-19 re-infection
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925083/
https://www.ncbi.nlm.nih.gov/pubmed/35306204
http://dx.doi.org/10.1016/j.ijid.2022.03.017
work_keys_str_mv AT inadamakoto antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT ishikanemasahiro antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT teradamari antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT matsunagaakihiro antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT maedakenji antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT iwamotonoriko antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT ujiiemugen antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT kutsunasatoshi antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT moriokashinichiro antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT ishizakayukihito antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT mitsuyahiroaki antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection
AT ohmagarinorio antibodyresponsesaftertwodosesofsarscov2mrna1273vaccineinanindividualwithhistoryofcovid19reinfection